目录
Immuno-oncology is a unique approach that uses the body"s immune system to fight cancer. These therapies activate an individual"s immune system, making it able to recognize cancer cells and destroy them. Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types. The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.
According to the report "Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to ", the global immuno-oncology market is anticipated to cross US$ 100 Billion by . The report provides a detailed analysis of the global immuno-oncology market. The report also provides the current and forecasted market for immuno-oncology.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market. Moreover, the report provides the sales of major marketed immuno-oncology drugs.
The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).
The report also sheds light on the geographic segmentation of the global immuno-oncology market. In , North America was estimated to account for the largest share. Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.
On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till .
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report. Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Dynamics
4.1 Drivers4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges4.2.1 Patent Expiry of Top-Selling Drugs
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment
4.2.3 Sky-High Development Costs of Cancer Immunotherapies
4.2.4 High Cost of Treatment
4.2.5 Lack of Awarenes
4.3 Opportunities4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increase in Survival
4.3.3 CAR-T Therapies: The Future of Cancer Care
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. Global Immuno-Oncology Market Outlook
6. Global Immuno-Oncology Market, by Product Class
6.1 Monoclonal Antibodies (mAbs)6.1.1 Naked Monoclonal Antibodies6.1.1.1 Rituxan (Rituximab)
6.1.1.2 Avastin (Bevacizumab)
6.1.1.3 Herceptin (Trastuzumab)
6.1.2 Conjugated Monoclonal Antibodies6.1.2.1 ADCETRIS (Brentuximab vedotin)
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
6.1.3 Bispecific Monoclonal Antibodies6.1.3.1 Blincyto (Blinatumomab)
6.1.4 Others
6.2 Therapeutic Vaccines6.2.1 Provenge
6.3 Immune Checkpoint Inhibitors6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)6.3.1.1 Yervoy (Ipilimumab)
6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death-1 and Programmed Death-Ligand 1)6.3.2.1 Opdivo (Nivolumab)
6.3.2.2 Keytruda (Pembrolizumab)
6.4 Others
7. Global Immuno-Oncology Market, By Major Indications
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. Global Immuno-Oncology Market, By Geography
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. Trends & Developments
9.1 Lucrative Investment Trends
9.2 Emergence of Targeted and Combination Therapies
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry
11. Pipeline Analysis of Immuno-Oncology
12. Competitive Landscape
12.1 Share of Major Players
13. Key Players Analysis
13.1 F. Hoffmann-La Roche AG
13.2 Celgene Corporation
13.3 Bristol-Myers Squibb
13.4 Merck & Co., Inc.
13.5 Novartis
13.6 AstraZeneca Plc
13.7 Pfizer Inc
13.8 Eli Lilly and Company
13.9 Johnson & Johnson
13.10 Amgen Inc.
List of Figures:
Figure 4-1: Global - Cancer Incidences (Million), , , 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), , , 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), -
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%),
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%),
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), -
Figure 6-4: Global - Rituxan Market (Billion US$), -
Figure 6-5: Global - Avastin Market (Billion US$), -
Figure 6-6: Global - Herceptin Market (Billion US$), -
Figure 6-7: Global - ADCETRIS Market (Million US$), -
Figure 6-8: Global - Kadcyla Market (Million US$), -
Figure 6-9: Global - Blincyto Market (Million US$), -
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), -
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), -
Figure 6-12: Global - Provenge Market (Million US$), -
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), -
Figure 6-14: Global - Yervoy Market (Million US$), -
Figure 6-15: Global - Opdivo Market (Million US$), -
Figure 6-16: Global - Keytruda Market (Million US$), -
Figure 6-17: Global - Others Market (Billion US$), -
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%),
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%),
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), -
Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%),
Figure 7-6: Global - Lung Cancer Market (Billion US$), -
Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%),
Figure 7-9: Global - Melanoma Market (Billion US$), -
Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%),
Figure 7-12: Global - Lymphoma Market (Billion US$), -
Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%),
Figure 7-15: Global - Leukemia Market (Billion US$), -
Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%),
Figure 7-18: Global - Other Cancer Market (Billion US$), -
Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%),
Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%),
Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%),
Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%),
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), -
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), -
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), -
Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), -
Figure 9-2: Major Investors in Immuno-Oncology Market (-)
Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%),
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%),
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%),
Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%),
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%),
Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%),
Figure 13-4: Celgene Corporation - Sales by Products (%),
Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%),
Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%),
Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%),
Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%),
Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%),
Figure 13-10: Novartis - Sales by Business Segments (%),
Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%),
Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%),
Figure 13-13: Novartis - Sales by Geography (%),
Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%),
Figure 13-15: AstraZeneca Plc - Revenue by Geography (%),
Figure 13-16: Pfizer Inc - Revenue by Business Segments (%),
Figure 13-17: Pfizer Inc - Revenue by Geography (%),
Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%),
Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%),
Figure 13-20: Eli Lilly and Company - Revenue by Geography (%),
Figure 13-21: Johnson & Johnson - Sales by Business Segments (%),
Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%),
Figure 13-23: Johnson & Johnson - Sales by Geography (%),
Figure 13-24: Amgen Inc. - Sales by Product (%),
Figure 13-25: Amgen Inc. - Sales by Geography (%),
List of Tables:
Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
Table 6-8: Ongoing Trials for Provenge
Table 6-9: Ongoing Trials for Yervoy
Table 6-10: Ongoing Trials for Opdivo
Table 6-11: Ongoing Trials for Keytruda
Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
Table 7-1: Global - Oncology Incidence by Geography ("000), &
Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments
Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Active Immuno-Oncology Programs
Table 11-2: Global - Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), -
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
Table 13-4: Celgene Corporation - Key Financials (Million US$), -
Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products
Table 13-6: Celgene Corporation - Product Pipeline
Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), -
Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-9: Bristol Myers Squibb - Product Pipeline
Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), -
Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-12: Merck & Co., Inc. - Product Pipeline
Table 13-13: Novartis - Key Financials (Billion US$), -
Table 13-14: Novartis - Commercialized Immuno-Oncology Products
Table 13-15: Novartis - Product Pipeline
Table 13-16: AstraZeneca Plc - Key Financials (Million US$), -
Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-18: AstraZeneca Plc - Product Pipeline
Table 13-19: Pfizer Inc - Key Financials (Billion US$), -
Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-21: Pfizer Inc - Product Pipeline
Table 13-22: Eli Lilly and Company - Key Financials (Million US$), -
Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-24: Eli Lilly and Company - Product Pipeline
Table 13-25: Johnson & Johnson - Key Financials (Billion US$), -
Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-27: Johnson & Johnson - Product Pipeline
Table 13-28: Amgen Inc. - Key Financials (Billion US$), -
Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-30: Amgen Inc. - Product Pipeline
